造血干细胞移植及急性白血病患者 liberalized 饮食与中性粒细胞减少饮食的随机非劣效性试验
该III期随机非劣效性试验纳入214例可评估的造血干细胞移植或急性白血病诱导化疗患者,比较 liberalized 饮食(LD,含新鲜果蔬)与中性粒细胞减少饮食(ND)。因LD组主要感染率超过预设停止边界,试验在第二次中期分析时终止:LD组主要感染率为31.4%,ND组为20.2%,差异11.2%(95%CI -0.4至22.9;LD未改善热量摄入,两组近三分之二患者报告关键营养问题,且症状、生活质量或生存无优势。结论认为LD并非ND的安全替代。
要点
- LD组主要感染率31.4%高于ND组20.2%,差异11.2%,试验因超过停止边界提前终止。
- LD未改善热量摄入,两组近三分之二患者存在关键营养问题。
- LD在症状、生活质量或生存方面均无优势,不建议替代ND。
核心结论
- 在HSCT患者和急性白血病患者中,LD不是ND的安全替代,因感染风险增加且无营养或其他获益。
研究设计与样本
- III期随机非劣效性试验,纳入214例可评估的造血干细胞移植或急性白血病诱导化疗患者,随机分配至ND或LD(含新鲜果蔬)。
主要发现
- LD组热量摄入未改善,两组近三分之二患者报告关键营养问题。
- LD组在症状、生活质量或生存方面无优势。
关键数值与推荐
- 主要终点为中性粒细胞减少期间发生任何主要感染,非劣效性界值为主要感染率差异≤10%。
- 试验在第二次中期分析时因LD组主要感染率超过预设停止边界而终止。
临床怎么用
- HSCT及急性白血病诱导化疗患者不应常规采用含新鲜果蔬的LD,应继续使用ND以降低感染风险。
- 需进一步研究改善营养而不牺牲安全性的饮食策略。
局限性
- 试验因LD组感染率超过停止边界而提前终止,可评估样本量为214例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients undergoing hematopoietic stem-cell transplantation (HSCT) or induction chemotherapy for acute leukemia (AL) generally receive a low-bacterial neutropenic diet (ND) to minimize infection from ingested microbes. Recent studies suggest that a more liberalized diet (LD) might be safe. However, those studies lacked robust designs to demonstrate noninferiority and did not address whether an LD improves caloric intake or nutritional status. This trial aimed to determine whether the rate of major infections in LD patients was noninferior to that in ND patients and whether an LD improved caloric intake and nutritional status. METHODS: In this phase III noninferiority trial, patients were randomly assigned to either an ND or LD, containing fresh fruits and vegetables. The primary end point was the development of any major infection during neutropenia. The noninferiority margin was set at a difference of ≤10% in the major infection rate. RESULTS: The trial was halted at the second interim analysis after enrolling 214 evaluable patients, because of the LD arm's major infection rate surpassing the predefined stopping boundary. In the LD arm, major infections occurred in 31.4% of patients compared with 20.2% of patients in the ND arm, a difference of 11.2% ([95% CI, -0.4 to 22.9]; P = .58). Furthermore, the caloric intake in the LD arm was not improved and nearly two thirds of patients on both diets reported critical nutritional problems. There was no advantage in symptoms, quality of life, or survival for the LD arm. CONCLUSION: These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit. Further dietary strategies are needed to improve nutrition without compromising safety.
引用
- Wingard JR, Lee JH, Li D, et al. Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia. J Clin Oncol. 2025. PMID: 41406403. doi:10.1200/JCO-25-00889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。